ASH: Daratumumab Beneficial for Patients With Multiple Myeloma

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 13, 2023.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival. These findings were published online Dec. 12 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in San Diego.

Pieter Sonneveld, M.D., Ph.D., from the Erasmus MC Cancer Institute in Rotterdam, Netherlands, and colleagues randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive D-VRd induction and consolidation therapy and lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group) in a phase 3 trial.

The researchers found that the risk for disease progression or death was lower in the D-VRd group than in the VRd group at a median follow-up of 47.5 months. The estimated percentage of patients with progression-free survival was 84.3 and 67.7 percent in the D-VRd and VRd groups, respectively, at 48 months (hazard ratio for disease progression or death, 0.42). The D-VRd group had a higher percentage of patients with a complete response or better (87.9 versus 70.1 percent) and a higher percentage of patients with minimal residual disease-negative status (75.2 versus 47.5 percent).

"These results further strengthen the existing evidence supporting the use of daratumumab in combination regimens for patients with newly diagnosed multiple myeloma," the authors write.

The study was partially funded by Janssen Research and Development, the manufacturer of daratumumab.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-14 00:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords